Sanctuary Advisors LLC Acquires New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sanctuary Advisors LLC bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 21,614 shares of the company’s stock, valued at approximately $449,000.

Other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after purchasing an additional 2,459 shares during the last quarter. Finally, EntryPoint Capital LLC grew its holdings in shares of Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after purchasing an additional 1,563 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NTLA shares. JPMorgan Chase & Co. lowered their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Canaccord Genuity Group reissued a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a report on Thursday, June 27th. Stifel Nicolaus decreased their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Price Performance

NTLA opened at $20.58 on Thursday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -3.84 and a beta of 1.76. Intellia Therapeutics, Inc. has a 1-year low of $17.09 and a 1-year high of $34.87. The business has a 50 day moving average price of $21.10 and a two-hundred day moving average price of $23.03.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same period last year, the business earned ($1.40) EPS. Intellia Therapeutics’s revenue for the quarter was down 48.5% compared to the same quarter last year. Equities analysts expect that Intellia Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.